Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FORCE

Financiado

Cerrado

Imaging the Force of Cancer

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy ef... ver más

31/07/2021

KINGS COLLEGE LOND...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 20 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-31

PHC-11-2015: Development of new diagnostic tools...

I+D

Cerrada hace 10 años

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

20 Participantes

KINGS COLLEGE LONDON

2.20M€ | Lider

PHILIPS MEDICAL SYSTEMS NEDE...

25.00K€ | Participante

ICR

631.70K€ | Participante

KANTONSSPITAL BASEL

78.63K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIO2008-06843-C04-01 AISLAMIENTO NO INVASIVO DE CELULAS TUMORALES CIRCULANTES EN... 121K€ Cerrado

OCTOPUS OCTOPUS Oncological Concurrent Tomographic Optoacoustics P... 161K€ Cerrado

SOLUS Smart optical and ultrasound diagnostics of breast cancer 4M€ Cerrado

RTI2018-099369-B-I00 FENOTIPADO MECANO-INERCIAL DE CELULAS CANCEROSAS 163K€ Cerrado

PID2021-128985OB-I00 NUEVA TECNOLOGIA NO INVASIVA PARA INHIBICION DE CRECIMIENTO... 150K€ Cerrado

BES-2012-055741 MEJORA DE LOS PROTOCOLOS PARA DIAGNOSTICO Y SEGUIMIENTO DE R... 43K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2015-12-09
Fecha Fin: 2021-07-31

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastatic potential could be gauged by measuring the forces exert by tumours. Furthermore, many solid tumours show a significantly increased interstitial fluid pressure (IFP) which prevents the efficient uptake of therapeutic agents. As a result, a reduction in IFP is recognized as a hallmark of therapeutic efficacy. Currently, there is no non-invasive modality that can directly image these forces in vivo. Our objective is the non-invasive measurement of both IFP within tumours as well as the forces they exert on their surrounding environment. This will be used to predict a tumour’s metastatic potential and importantly, changes in these forces will be used to predict the therapeutic efficacy of drug therapy. To attain this goal, the biomechanical properties of the tumour and its neighbouring tissue will be measured via MR-elastography at various measured deformation states. Resultant images will be used to reconstruct images of the internal and external forces acting on the tumour. We call this novel imaging modality Magnetic Resonance Force (MRF) imaging . We will calibrate MRF via cell cultures and pre-clinical models, and then test the method in breast, liver, and brain cancer patients. Thereby, we will investigate whether MRF data can predict metastatic spread and measure IFP in patients. We will also investigate the potential to non-invasively modulate the force environment of cancer cells via externally applied shear forces with the aim of impacting cell motility and proliferation. This can provide novel mechanism for anticancer therapeutic agents via mechanotransduction.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores